O-23: Hysteroscopic Polypectomy without Cycle Cancellation in IVF/ICSI Cycles: A Matched Case-Control Study
The effect of hysteroscopic polpectomy for endometrial polyps during treatment cycles is still debated and further studies are necessary to evaluate beneficial effect of this procedure.
Materials and methods
This matched case-control study compared retrospectively 86 women with and without hysteroscopic polypectomy who underwent in vitro fertilization and / or Intracytoplasmic sperm injection (IVF/ICSI) cycles during January 2011 to December 2013. We evaluated the recorded data of one hundred sixty women were diagnosed with endometrial polyps less than 2 cm by hysteroscopy during the period of the study in Royan Institute. In fifty-eight patients, polyp resection was performed through hysteroscopic polypectomy during ovarian stimulation in the standard treatment cycles. The interval between polypectomy and embryo transfer was 3–17 days. The hysteroscopy polypectomy during stimulation were approved by the Royan Institute Review Board and Ethics committee. All the women were treated by hysteroscopic polypectomy after informed consent had been taken. The control group was selected among 102 women who were not treated by hysteroscopic polypectomy by matching for age and polyp size. The outcomes of IVF/ICSI cycles were compared between case and control groups using Student t and chi-square tests.
Finally 43 patients in each group were matched for age and polyp size. Results showed the two groups were comparable in terms of body mass index, duration and cause of infertility, number of previous cycles, type and duration of ovarian stimulation, number of retrieved oocytes, number and quality of transferred embryos, fertilization and implantation rates. The clinical pregnancy and live birth rates were similar between case and control groups (34.9 vs. 32.5 and 30.2 vs. 27.9%, P=0.9 and P=0.8 respectively).
In present study, we found no beneficial or disadvantage effects of hysteroscopic polypectomy during ovarian stimulation on IVF/ICSI outcomes. We suggest further clinical randomized trials to confirm these results.